Inmed reports second fiscal quarter 2024 financial results and provides business update

Advancing two new preclinical programs in alzheimer's and age-related macular degeneration closed calendar year 2023 with cash position of us$9.5 million 164% revenue growth in the commercial baymedica subsidiary vancouver, british columbia--(newsfile corp. - february 13, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today reports financial results for the second quarter of the fiscal year 2024 which ended december 31, 2023. the company's full financial statements and related md&a for the second quarter ended december 31, 2023, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
INM Ratings Summary
INM Quant Ranking